Inhibikase Therapeutics, Inc. Common Stock Share Price
NYSE: IKTHealthcare
Live Inhibikase Therapeutics, Inc. Common Stock Share Price Chart
O H L
Inhibikase Therapeutics, Inc. Common Stock Performance Overview
Days Range
▼
$2.32Low
$2.33High
Markets Today
| Previous Close | $2.30 |
|---|---|
| Open | $2.33 |
| Volume | 97,771 |
| Day's Range | $2.32 - $2.33 |
| 52W Range | $1.33 - $2.61 |
| Market Cap | $322.33 M |
Historical Performance
| 1M Returns | -4.17 |
|---|---|
| 3M Returns | +25.68 |
| 6M Returns | +25.68 |
| 1Y Returns | +49.35 |
| 5Y Returns | -81.21 |
| 10Y Returns | NA |
Inhibikase Therapeutics, Inc. Common Stock Fundamentals
| Market Cap | $322.33 M |
|---|---|
| Dividend yield | 0.00 |
| PE Ratio | 0.00 |
| PEG Ratio | N/A |
| Revenue | $0.00 |
| ROE TTM | -0.36 |
| EPS TTM | $-0.44 |
| Quarterly Earnings Growth YOY | N/A |
| PB Ratio | 1.99 |
| EBITDA | $-51.91 M |
| Profit Margin | N/A |
| Market Cap | $322.33 M |
|---|---|
| Dividend yield | 0.00 |
| PE Ratio | 0.00 |
| PEG Ratio | N/A |
| Revenue | $0.00 |
| ROE TTM | -0.36 |
| EPS TTM | $-0.44 |
|---|---|
| Quarterly Earnings Growth YOY | N/A |
| PB Ratio | 1.99 |
| EBITDA | $-51.91 M |
| Profit Margin | N/A |
Inhibikase Therapeutics, Inc. Common Stock Profit & Loss
Quarterly
| Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| Total Revenue + | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit + | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$14.60 M | -$10.83 M | -$12.77 M | -$13.78 M | -$17.84 M | -$21.05 M |
| EBITDA | -$14.59 M | -$10.81 M | -$12.74 M | -$13.78 M | -$17.84 M | -$21.05 M |
| Interest Expense | $0 | $0 | $838.09 K | -$2.67 M | $0 | $0 |
| Depreciation | $12.65 K | $24.16 K | $23.69 K | $0 | $0 | $0 |
| Income Before Tax | -$13.68 M | -$9.92 M | -$11.93 M | -$12.73 M | -$16.38 M | -$19.59 M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income + | -$13.68 M | -$9.92 M | -$11.93 M | -$12.73 M | -$16.38 M | -$19.59 M |
| Net Profit Margin | - | - | - | - | - | - |
Inhibikase Therapeutics, Inc. Common Stock Financials Balance Sheet In USD
Quarterly
| Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| Share Capital | $74.34 K | $74.52 K | $74.81 K | $131.69 K | $132.03 K | $132.03 K |
| Reserve & Surplus | -$108.10 M | -$118.02 M | -$129.95 M | -$142.66 M | -$159.09 M | -$178.72 M |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Liabilities | $8.55 M | $8.80 M | $6.70 M | $8.30 M | $5.71 M | $10.26 M |
| Total Liabilities | $8.55 M | $8.80 M | $6.70 M | $8.30 M | $5.71 M | $10.26 M |
| Fixed Assets | $47.84 K | $23.69 K | $0 | $0 | $0 | $0 |
| Current Assets | $94.16 M | $88.49 M | $78.54 M | $180.11 M | $172.18 M | $162.34 M |
| Total Assets | $94.28 M | $88.85 M | $79.59 M | $181.20 M | $173.33 M | $163.59 M |
Inhibikase Therapeutics, Inc. Common Stock Cash Flow
Quarterly
| Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| Net Income | -$13.68 M | -$9.92 M | -$11.93 M | -$12.73 M | -$16.38 M | -$19.59 M |
| Operating Cash Flow | -$4.10 M | -$5.57 M | -$10.59 M | -$7.52 M | -$12.06 M | -$12.44 M |
| Investing Cash Flow | $21.05 M | $9.84 M | -$28.75 M | -$98.85 K | -$80.48 M | -$5.91 M |
| Financing Cash Flow | $0 | $31.77 K | -$134.13 K | $108.57 M | $2.90 M | -$14.49 K |
| Change in Cash | $16.95 M | $4.30 M | -$39.47 M | $100.95 M | -$89.65 M | -$18.37 M |
Inhibikase Therapeutics, Inc. Common Stock Return Calculator
The Inhibikase Therapeutics, Inc. Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.
Returns Estimator
Based on past performance of this fund
ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$1,887
Invested Amount$10,000
Est. Returns$-8,113
About Inhibikase Therapeutics, Inc. Common Stock
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Popular Stocks
FAQs
What is the share price of Inhibikase Therapeutics, Inc. Common Stock today?
Inhibikase Therapeutics, Inc. Common Stock (IKT) share price as of September 18, 2026 is $2.31. If you are investing from India, you can always check the valuation in the INR before investing.
Can Indian Investors purchase shares of Inhibikase Therapeutics, Inc. Common Stock?
Yes, Indian Investors can invest in the Inhibikase Therapeutics, Inc. Common Stock (IKT) Share by opening an international trading account with Angel One.
How can I purchase Inhibikase Therapeutics, Inc. Common Stock shares in India?
Purchasing Inhibikase Therapeutics, Inc. Common Stock (IKT) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Inhibikase Therapeutics, Inc. Common Stock (IKT) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Can I buy Fractional shares of Inhibikase Therapeutics, Inc. Common Stock?
Yes, you can purchase fractional shares of Inhibikase Therapeutics, Inc. Common Stock (IKT) or any other US company shares in Angel One for any dollar amount.
What is the market capitalization value of Inhibikase Therapeutics, Inc. Common Stock?
The market capitalization of Inhibikase Therapeutics, Inc. Common Stock on September 18, 2026, is $322.33 M.
In which sector Inhibikase Therapeutics, Inc. Common Stock belongs?
Inhibikase Therapeutics, Inc. Common Stock operates in the Healthcare sector, specifically in the Healthcare industry.
What documents are required to invest in Inhibikase Therapeutics, Inc. Common Stock stocks?
In order to invest in Inhibikase Therapeutics, Inc. Common Stock (IKT) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.
Diversify Your Portfolio with US Stocks
Invest in Wall Street Giants from India
